Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.
The striatum is particularly sensitive to the irreversible inhibitor of succinate dehydrogenase 3-nitropropionic acid (3-NP). In the present study, we examined early changes in behavior and dopamine and glutamate synaptic physiology created by a single systemic injection of 3-NP in Fischer 344 rats. Hindlimb dystonia was seen 2 h after 3-NP injections, and rats performed poorly on balance beam and rotarod motor tests 24 h later. Systemic 3-NP increased NMDA receptor-dependent long-term potentiation (LTP) at corticostriatal synapses over the same time period. The 3-NP-induced corticostriatal LTP was not attributable to increased NMDA receptor number or function, because 3-NP did not change MK-801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine] binding or NMDA/AMPA receptor current ratios. The LTP seen 24 h after 3-NP was D(1) receptor dependent and reversed by exogenous addition of dopamine or a D(2) receptor agonist to brain slices. HPLC and fast-scan cyclic voltammetry revealed a decrease in dopamine content and release in rats injected 24 h earlier with 3-NP, and much like the enhanced LTP, dopamine changes were reversed by 48 h. Tyrosine hydroxylase expression was not changed, and there was no evidence of striatal cell loss at 24-48 h after 3-NP exposure. Sprague Dawley rats showed similar physiological responses to systemic 3-NP, albeit with reduced sensitivity. Thus, 3-NP causes significant changes in motor behavior marked by parallel changes in striatal dopamine release and corticostriatal synaptic plasticity.
Akopian
Garnik
G
Davis School of Gerontology, University of Southern California, Los Angeles, California 90089, USA.
Crawford
Cynthia
C
Beal
M Flint
MF
Cappelletti
Maurand
M
Jakowec
Michael W
MW
Petzinger
Giselle M
GM
Zheng
Ling
L
Gheorghe
Stacey L
SL
Reichel
Carmela M
CM
Chow
Robert
R
Walsh
John P
JP
D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D003292:Convulsants / Q000633:toxicity; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D018698:Glutamic Acid / Q000378:metabolism; D002534:Hypoxia, Brain / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D017774:Long-Term Potentiation / Q000502:physiology*; D008297:Male; D009068:Movement / Q000187:drug effects / Q000502:physiology; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009498:Neurotoxins / Q000633:toxicity; D009574:Nitro Compounds / Q000633:toxicity; D011422:Propionates / Q000633:toxicity; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D013045:Species Specificity; D009435:Synaptic Transmission / Q000502:physiology*; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D003292:Convulsants; D018491:Dopamine Agonists; D009498:Neurotoxins; D009574:Nitro Compounds; D011422:Propionates; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid; C015392:3-nitropropionic acid; D004298:Dopamine
J Toxicol Clin Toxicol. 1995;33(4):363-7
7629905
Neurotox Res. 2005 Nov;8(3-4):259-66
16371320
J Neurosci. 1993 Oct;13(10):4181-92
7692009
Brain Res. 2005 Jun 21;1047(2):148-58
15901483
Neuroscience. 1999 Mar;90(3):1031-41
10218802
Ann Neurol. 1999 May;45(5):640-51
10319887
Exp Neurol. 2007 Oct;207(2):218-26
17673201
Lancet Neurol. 2003 Oct;2(10):622-9
14505584
Cereb Cortex. 2003 Nov;13(11):1251-6
14576216
Nat Neurosci. 2001 Dec;4(12):1217-23
11694884
Neuropathol Appl Neurobiol. 1998 Dec;24(6):487-97
9888159
J Neurosci. 1997 Aug 1;17(15):5738-46
9221772
Eur J Neurosci. 2001 Mar;13(6):1071-7
11285003
Proc Natl Acad Sci U S A. 1989 Nov;86(21):8570-4
2479025
J Neurochem. 1994 May;62(5):1878-86
8158136
J Neurophysiol. 2001 Jan;85(1):117-24
11152712
J Neurochem. 1998 Dec;71(6):2642-4
9832167
J Neurochem. 1994 Nov;63(5):1772-81
7523600
Acta Neuropathol. 1987;72(3):286-97
3564909
Brain Res Bull. 1999 Mar 1;48(4):395-9
10357071
Anal Biochem. 1976 May 7;72:248-54
942051
Neuropharmacology. 2003 May;44(6):787-800
12681377
NeuroRx. 2005 Jul;2(3):396-409
16389304
Neuron. 2006 May 4;50(3):443-52
16675398
Mol Cell Biochem. 1982 Mar 19;43(2):65-80
6123940
Biomed Environ Sci. 1992 Jun;5(2):161-77
1642790
J Neurosci. 1998 Dec 1;18(23):10116-27
9822765
Neuroscience. 2001;106(1):95-101
11564420
Neurobiol Aging. 1992 Mar-Apr;13(2):325-32
1522947
J Neurophysiol. 1999 Dec;82(6):3575-9
10601483
Curr Opin Neurol. 1994 Dec;7(6):542-7
7866587
Neuroscience. 2002;114(2):317-26
12204201
J Neurotrauma. 2000 Mar;17(3):251-60
10757330
Nature. 2001 Sep 6;413(6851):67-70
11544526
Neural Netw. 2002 Jun-Jul;15(4-6):507-21
12371508
J Neurosci. 2004 Aug 25;24(34):7482-90
15329395
Neurobiol Dis. 2006 Apr;22(1):143-52
16326108
J Neurosci. 2000 Jan 1;20(1):1-7
10627575
Eur J Neurosci. 2002 Jun;15(12):2053-6
12099912
Neuropathol Appl Neurobiol. 2000 Jun;26(3):232-42
10886681
J Gerontol. 1977 May;32(3):258-78
66246
Brain Res Bull. 1995;36(6):549-56
7538873
Neuropharmacology. 2004 May;46(6):761-9
15033336
Nature. 2007 Feb 8;445(7128):643-7
17287809
Neuroreport. 2004 Mar 1;15(3):413-6
15094494
Brain Res Bull. 1994;33(3):281-8
7904889
Neurosci Lett. 2004 Jan 16;354(3):234-8
14700739
Neurol Sci. 2003 Oct;24(3):180-1
14598076
J Neurophysiol. 2002 Dec;88(6):3010-20
12466426
J Neurosci. 2000 Nov 15;20(22):RC106
11069975
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2446-50
7708662
Exp Neurol. 1993 May;121(1):57-64
8495711
J Cereb Blood Flow Metab. 2002 Jul;22(7):798-809
12142565
J Cereb Blood Flow Metab. 2000 Jan;20(1):119-29
10616800
Synapse. 2002 Jun 1;44(3):188-97
11954051
Neurosci Lett. 1995 Sep 8;197(2):85-8
8552286
J Neurochem. 1993 Sep;61(3):1147-50
7689641
J Neurophysiol. 2000 Sep;84(3):1422-9
10980015
J Neurosci. 1996 Dec 1;16(23):7478-86
8922403
J Neurophysiol. 1997 Feb;77(2):853-62
9065854
Brain Res. 2005 Apr 8;1040(1-2):112-20
15804432
Can J Neurol Sci. 2000 May;27(2):152-9
10830350
Neuropharmacology. 1999 Feb;38(2):323-6
10218876
Synapse. 2000 Dec 1;38(3):271-80
11020230
Brain Res. 1994 May 23;646(2):242-6
8069670
Neurochem Res. 2003 Dec;28(12):1883-9
14649731
Neurobiol Dis. 2002 Aug;10(3):410-26
12270701
Can J Neurol Sci. 1991 Nov;18(4):492-8
1782616
J Neurosci. 2004 Nov 24;24(47):10652-9
15564581
Neurotoxicol Teratol. 2000 Nov-Dec;22(6):799-804
11120384
Funct Neurol. 2001;16(4 Suppl):149-52
11996510
Eur J Neurosci. 2006 Dec;24(11):3134-40
17156374
J Neurosci. 2007 May 16;27(20):5291-300
17507552
Anal Chem. 1996 Sep 1;68(17):3054-8
21619374
J Neurosci. 1992 Nov;12(11):4224-33
1359031
J Neurosci. 2001 Jul 15;21(14):5110-20
11438586
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Neuroscience. 2000;97(3):521-30
10828534
Ann Neurol. 1988 Nov;24(5):670-6
2904792
Eur J Neurosci. 2003 Aug;18(4):759-67
12925002